Vera Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vera Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($80.29M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($76.53M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($76.53M) | Aug 5, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($51.69M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($51.69M) | May 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($51.69M) | Nov 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($46.63M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($33.71M) | Aug 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($33.71M) | Nov 5, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($28.38M) | Nov 5, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($28.38M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($28.38M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($20.10M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.16M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($20.16M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($30.07M) | May 10, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($30.07M) | Nov 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($30.07M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($24.68M) | Nov 9, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($14.85M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($83.93M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($80.14M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($57.19M) | May 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($49.80M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($37.34M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($31.11M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($21.76M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.97M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($31.26M) | May 10, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($25.24M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($15.06M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($17.02M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($7.25M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.85M) | Aug 10, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($4.72M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($4.04M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($3.17M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($2.47M) | Jun 24, 2021 |